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Abstract Tumor-associated myeloid cells have been im-
plicated in regulating many of the “hallmarks of cancer”
and thus fostering solid tumor development and metastasis.
However, the same innate leukocytes also participate in
anti-tumor immunity and restraint of malignant disease.
While many factors regulate the propensity of myeloid cells
to promote or repress cancerous growths, polarized adap-
tive immune responses by B and T lymphocytes have been
identified as regulators of many aspects of myeloid cell
biology by specifically regulating their functional capabil-
ities. Here, we detail the diversity of heterogeneous B and T
lymphocyte populations and their impacts on solid tumor
development through their abilities to regulate myeloid cell
function in solid tumors.
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1 Introduction
Virchow first described leukocyte infiltration of solid
tumors in the 1800s; however, only recently have we
begun to understand the diverse regulatory roles played by
immune cells during cancer development. Historically,
leukocytes found in and around developing tumors were
thought to represent an attempt by the host to eradicate
neoplastic cells. Indeed, some leukocytes, including CD8
+
cytotoxic T lymphocytes (CTLs) and natural killer (NK)
cells, do play a critical role in restraining tumor develop-
ment [1]. However, we now appreciate that the significance
of these anti-tumor programs can be thwarted by other
subsets of leukocytes that instead foster tumor development
[2–5]. Immune-competent mouse models of human cancer
have enabled a detailed evaluation of the tumor-promoting
capacity of several subsets of myeloid cells, including mast
cells (MCs), monocytes, granulocytes/neutrophils, and
macrophages, as well as some subsets of lymphocytes [6, 7].
However, depending on their differentiation status and
immune microenvironment, subpopulations of these same
cells can also support tumor rejection and response to anti-
cancer therapy [2, 8, 9], thus indicating that pro- and anti-
tumor programming of leukocytes is dynamic. In this review,
we discuss recent insights into the role of B and T
lymphocytes as “gatekeepers” of myeloid cell bioactivity
(Fig. 1) and how recognition of these dynamic interactions
reveals novel opportunities for anti-cancer therapy.
2 Paradoxical role of CD4
+ T lymphocytes in solid
tumor development
In contrast to CD8
+ CTLs that play well-defined roles in
hindering cancer development, the functional significance
of CD4
+ T lymphocytes in tumor progression appears more
paradoxical. For example, retrospective evaluation of colon
and lung carcinomas revealed that extensive infiltration of
tumors by CD4
+ T cells correlates with favorable clinical
outcome, whereas in breast and renal cancers exhibiting
similar infiltrations instead correlates with decreased overall
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DOI 10.1007/s10555-010-9223-6survival [10–13]. Analysis of mouse models of human
cancer have provided some clarity for these disparate
findings and revealed that etiology and organ specificity
matters with regards to how CD4
+ Tc e l l sa i do rc o n s t r a i n
tumor progression. Schreiber and colleagues demonstrated
that, whereas CD4
+ T cell deficiency enhances methylcho-
lanthrene (MCA)-initiated sarcoma development [14], carci-
noma development on the other hand is inhibited following
two-stage squamous carcinogenesis [15, 16]. Similarly, in a
mouse model of skin and cervical carcinoma development
where oncogenes from human papilloma virus type 16
(HPV16) are expressed under the control of the keratin 14
promoter, skin carcinoma formation is modestly attenuated
by CD4
+ T cell deficiency, whereas cervical carcinoma
development is significantly enhanced [17, 18]. Together,
these observations demonstrate that immune responses
accompanying tumor development are organ dependent
and, based on the neoplastic microenvironment, engage
either pro- or anti-tumor immune programs. The heteroge-
neity of CD4
+ T cell subsets that accumulate in tissues may
be at the heart of these paradoxical findings.
3 CD4
+ T lymphocyte heterogeneity
CD4
+ T cells represent a highly heterogeneous population
of cells that develop along different functional lineages
depending upon polarizing cytokine signals during activa-
tion by antigens [19]. Classically, CD4
+ T lymphocyte
subsets include TH1 and TH2 lineages that are characteris-
tically fostered by exposure to interleukin (IL)12 and IL4,
respectively. Following activation, CD4
+ T cells assuming
the TH1 fate secrete interferon (IFN)γ, tumor necrosis
factor (TNF)α, IL2, and IL12 [20]. Through the production
of these cytokines, TH1 cells regulate immune surveillance
programs by up-regulating antigen processing and presen-
tation on major histocompatability complex (MHC) I and II
molecules by professional antigen presenting cells (APCs)
and as such can regulate the duration and magnitude of
CD8
+ CTL responses [21]. In addition, following strong
antigen-specific activation, TH1 cells can directly kill tumor
cells by releasing high levels of IFNγ, TNFα and cytolytic
granules. Thus, when present, TH1 responses can directly
and indirectly regulate anti-tumor programs that restrain
cancer development.
In contrast, TH2 CD4
+ T cells express high levels of IL4,
-5, -6, -10, and -13 that, together, alter adaptive immunity
by inducing T cell anergy, inhibiting T cell-mediated
cytotoxicity as well as fostering humoral immune responses
directed by B cells [22, 23]. The TH2 cytokines IL4 and
IL13 are important mediators of CD4
+ T cell functionality
in vitro,T H2C D 4
+ T cells inhibit apoptosis and induce
proliferation of breast carcinoma cells; in vivo, IL4 emanat-
ing from CD4
+ T cells fosters breast cancer growth [24, 25].
Consistent with these findings, a high ratio of TH2
+ to TH1
+
cells correlates with parameters of clinical disease progres-
sion, such as increased tumor size and grade and lymph node
metastasis of breast cancers [26].
Adding to this TH1 versus TH2 paradigm, CD4 lineages
have recently expanded to include a TH17 subset that is
differentiated by a combination of IL6 and transforming
growth factor (TGF)β and mediate their effects through
secretion of IL17, -21, and -22, [27–29]. TH17 cells are
thought to play an important role in protection against some
extracellular pathogens and in regulating auto-immune
disease [30, 31]. As such, TH17 cells have been implicated
in the development of inflammation-associated colonic
tumors in response to pathogenic bacteria [32]. TH17 cell
infiltration has also been observed in patients with colon,
ovarian, prostate, and hepatocellular carcinoma where high
numbers of IL17-producing cells correlates with poor
prognosis [33–35]. In mouse models of non-small cell lung
cancer (NSCLC), IL17 enhanced tumor growth by promot-
ing development of angiogenic vasculature [36, 37]. In
contrast, in a B16 melanoma model, IL17 depletion
rendered mice more susceptible to metastasis [38], a
phenotype that was blocked by adoptive transfer of
tumor-specific TH17 cells that fostered immune surveil-
lance by CD8
+ CTLs and dendritic cells (DCs) [38].
Together, these experimental findings indicate that the role
Fig. 1 Adaptive immune responses control tumor-associated myeloid
cell bioactivity and tumor progression. Polarized responses by
adaptive immune cells alter the balance between pro- and anti-tumor
myeloid cell bioactivities. When the host’s response to neoplastic cell
growth results in the production of TH1 cytokines by CD4
+ T
lymphocytes and NK cells, myeloid cells in turn induce programs
promoting tumor regression and/or dormant disease. However, when
these adaptive immune responses include chronic B lymphocyte
activation and IgG production in combination with TH2 and TREG
lymphocyte activation, programs of immune suppression, angiogene-
sis, tissue remodeling, and invasion are favored in myeloid cells and
contribute to tumor progression and metastasis
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may also be context dependent.
In addition to TH1, TH2, and TH17 CD4
+ effectors,
populations of CD4
+FoxP3
+ T regulatory (TREG) cells are
also thought to play a considerable role in regulating tumor
immunity. In human cancers, increased prevalence of
CD4
+FoxP3
+ TREG cells correlates with increased survival
for follicular lymphoma [39], while it instead correlates with
poor prognosis in pancreatic ductal carcinoma [40], non-small
cell lung cancer [41], renal cell carcinoma [11], and breast
carcinoma [42]. Suppression of the anti-tumor activities of
CD8
+ CTLs, NKs, and DCs is at the heart of how TREG cells
control tumor development [43, 44]; however, the multitude
of mechanisms whereby they regulate anti-tumor programs
suggest the existence of distinct tissue-specific sub-
populations of TREG cells, each endowed with or capable of
various bioeffector activities [45–47]. Mechanistic studies
have revealed that TREG cells support pro-tumor immunity
not only by increasing local levels of immunosuppressive
cytokines including TGFβ, IL35, and IL10 but also by direct
cytolytic effects through production of perforin and gran-
zyme. In addition, TREG cells can disrupt the metabolic
activity of cyclic adenosine monophosphate (cAMP) transfer,
as well as inhibit APC function by inducing binding of
CTLA-4 to CD80/86 [44, 48].
Thus, while it is now clear that a spectrum of CD4
+ T
cell subtypes are present in human tumors of essentially all
types, the role they play in promoting or repressing tumor
development likely has to do with the type of CD4
+ T cell
subtype that is either recruited to or accumulates within
each distinct tumor microenvironment. These in turn then
regulate anti-tumor programs by professional cytotoxic
cells (CD8
+ T CTLs and NK cells), as well as regulating
pro-tumor properties of a diverse array of myeloid cell
subtypes as discussed below.
4 Myeloid heterogeneity and tumor development
Innate immune cells of myeloid origin, e.g., granulocytes
(neutrophils, basophils, and eosinophils), DCs, macro-
phages, NK cells, and MCs, are also prominent components
of pre- and malignant tissues and functionally contribute to
cancer development by releasing a myriad of cytokines,
chemokines, matrix metalloproteinases, serine proteases,
DNA-damaging molecules (reactive oxygen species), his-
tamine, and other bioactive mediators that regulate tissue
remodelling and angiogenesis [49–53], suppress anti-tumor
immunity [54–56], and enhance tumor cell survival,
migration, and metastasis [57, 58].
Nucleated hematopoietic cells that have been directly
implicated in tumor angiogenesis include MCs [51], tumor-
associated macrophages (TAMs) [5, 23, 59], Tie2-
expressing monocytes [50, 60], neutrophils [52], DC
precursors [61], and myeloid immune suppressor cells
[62, 63]. Other hematopoietic cell types, such as platelets
[64], eosinophils [65], and hematopoietic progenitors [66],
also participate in angiogenic processes, but it remains to be
established whether they can directly promote tumor
angiogenesis, rather than having a broader function in
supporting tissue inflammation and remodelling.
In contrast, these same myeloid cell lineages also foster
tumor rejection by inducing angiostatic programs, enhanc-
ing CTL and NK responses, and directly inducing tumor
cell death [13]. As an example of these paradoxical roles,
studies from several laboratories have reported that TAMs
enhance angiogenesis and metastasis of malignant mam-
mary tumors [25, 67, 68]. In contrast, TAMs exposed to
toll-like receptor (TLR) ligands and/or IFNγ directly lyse
mammary tumor cells, increase antigen presentation, and
secrete angiostatic proteins such as CXCL10 and 11 [8, 9 ,
69]. These distinct bioactivities are mirrored in neutrophils,
MCs, and DCs and may be due to the inherent plasticity of
myeloid lineage cells regulated by local factors present in
distinct tissue and/or organ microenvironments.
The bioactive states of macrophages, as well as other
myeloid cells, have been classified according to TH1 and
TH2 nomenclature, referred to as M1 (classical) or M2
(alternative) activation, respectively [2, 70, 71] (Fig. 1). M1
macrophages are regulated by TH1 cytokines including
IFNγ, TNFα, and granulocyte monocyte-colony stimulat-
ing factor (GM-CSF) that enhance macrophage cytotoxic
activity, production of pro-inflammatory cytokines, and
antigen presentation capacity [70, 71]. In contrast, tissue
macrophages can achieve various alternatively activated
M2 states following exposure to TH2 cytokines, including
IL4 or IL13 (M2a), potentiation by immune complexes and
TLR ligands (M2b) or immunosuppressive cytokines
including IL10 or TGFβ and/or glucocorticoid hormones
(M2c) [70].
The general hallmarks of M2 macrophages include high
levels of IL10, IL1Ra, IL1 decoy receptor CCL17 and
CCL22 secretion, high expression of mannose, scavenger
and galactose-type receptors, low expression of IL12, as
well as poor APC capability. Intriguingly, although these
alternative activation states (M2a, b, and c) share many
phenotypic characteristics, they are distinct and induce
individual context-dependent environmental responses. For
example, induction of an M2c phenotype by IL10 results in
highly immune suppressive macrophages that can also
produce matrix components such as versican or PTX3. In
contrast, TH2 cytokine induction of M2a TAMs induces
expression of fibronectin, as well as catabolism of L-
arginine by arginase that in turn leads to increased collagen
synthesis and matrix remodeling [70, 72]. Our own work
has revealed that IL4 and/or IL13 activation of macro-
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epidermal growth factor, TGFβ, and basic fibroblast
growth factor that together regulate invasive, angiogenic,
and immune-suppressive programs [25] (unpublished data).
Both M2a and M2b macrophages down-regulate the pro-
inflammatory cytokines IL1, IL6, and TNFα [73], whereas
induction of M2b macrophages by immune complexes
induces these same inflammatory cytokines in addition to
IL10 and also likely enhances vascular responses such as
endothelial migration and vessel dilation [74]. Thus, M2-
polarized cells promote scavenging of debris, angiogenesis,
and remodeling and repair of wounded/damaged tissues.
Parallel and non-redundant activity states have also been
defined for DCs (i.e., DC1, DC2) [75] and neutrophils (i.e.,
N1, N2) [76] (Fig. 1).
To address pro- versus anti-tumor capabilities of these
opposing states, Hagemann and colleagues demonstrated
that by “reprogramming” M2 TAMs through deletion of
IKKβ macrophage phenotype could be switched from
immunosuppressive to actively promoting immune surveil-
lance, as reflected by decreases in IL10 and arginase-1
expression and increased IL12 and nitric oxide production
together resulting in decreased ovarian tumor growth
through recruitment and activation of NK cells [67, 77].
Again, organ specificity and/or etiology may play a role in
regulating how reprogramming can be achieved. In a mouse
model of squamous carcinogenesis, we recently reported that
FcγR signaling in myeloid cells directly regulates whether
myeloid cells enhance or repress cancer development, which
correlate with their unique gene expression signatures that
reflect M1 versus M2 and DC1 versus DC2 programs [74].
These data indicate the significance of reprogramming
myeloid cell phenotypes to affect tumor outcome. The major
question that arises with regards to this capability then
becomes what are the cellular and molecular programs in
tissues and/or tumors that regulate the bioactive state of these
important myeloid cells and how recognition of these can be
translated into anti-cancer therapy.
5 T lymphocytes as regulators of anti-tumor
macrophages
Establishment of an immune reaction in homeostatic tissue
typically involves activation of NK cells in response to
stress signals or infectious agents, whom by their produc-
tion of IFNγ in turn prime macrophages towards an M1
state, culminating in enhanced presence of macrophages
with cytotoxic capability [71]. However,productionofIFNγ
by NK cells is generally transient and therefore insufficient to
sustain M1 macrophage polarization; thus, IFNγ-producing
TH1 cells are critical for immune responses requiring
sustained M1 macrophage bioactivities. In tumors, studies
by Corthay and colleagues demonstrated that TH1 cell
regulation of locally activated M1 macrophages were
significant and fostered rejection of myeloma and lympho-
mas in the absence of CTL responses [69, 78]. Moreover,
expression of IL12 and IFNγ by TH1 cells can combine to
enhance anti-tumor responses by NK and NK-T cells by up-
regulating expression of NK receptors such as NKG2D (in
response to IL12) and expression of NK receptor ligands
such as RAE1 on target cells (in response to IFNγ)[ 79]. TH1
responses then in turn favor anti-tumor NK and macrophage
responses that eliminate neoplastic cells. However, while
TH1 cells are antigen specific, tumoricidal macrophages exert
indiscriminate cell killing activity. Thus, multiple immuno-
suppressive programs have evolved to eliminate the adverse
autoimmune pathologies, such as rheumatoid arthritis, that
are associated with over-activation of these M1 responses
[80]; unfortunately, many of these immunosuppressive
programs are usurped by developing cancers.
6 T lymphocytes as regulators of pro-tumor myeloid
cells
In contrast to induction of tumor-immune surveillance
programsby TH1c e l l s ,T REG and TH2 cells have the capacity
to induce alternative activation states of macrophages, DCs,
and neutrophils involved in promoting cancer development.
Studies of human TREGs have demonstrated their ability to
block classical activation of macrophages and instead foster
immunosuppressive myeloid phenotypes through the pro-
duction of IL10 and TGFβ [81]. Similar biology may apply
to neutrophils, as recently reported by Fridlender and
colleagues who found that loss of TGFβ signaling through
ALK4/5 inhibition resulted in recruitment of N1-polarized
neutrophils with tumoricidal bioactivities [76]. While TGFβ
in the tumor microenvironment is produced by multiple cell
types, these data may indicate that TREG cells suppress N1
tumoricidal responses through production of TGFβ and, as
such, favor pro-tumor N2 or immature monocyte (IMC)
phenotypes. Our own work has demonstrated that CD4
+ TH2
cells in mammary tumors promote M2 responses in TAM
and IMCs that in turn enhance pulmonary metastasis [25].
Together, these data indicate that the balance of TH1v e r s u s
TH2/TREG responses regulates the pro- versus anti-tumor
programming of tumor-associated myeloid cells.
7 B lymphocytes as regulators of myeloid cells
during cancer development
B lymphocytes constitute a central component of humoral
immunity and not only serve in antibody production but
also in antigen presentation and cytokine secretion. In
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stimulatory molecules as well as secretion of pro-
inflammatory cytokines are critical for regulating CD4
+
and CD8
+ T cell activation, expansion, antigenic spreading,
and memory T lymphocyte formation. The heterogeneity of
B lymphocyte responses has been recently recognized and
diverse B cell subtypes with either pro-immune or
regulatory properties have been identified in vivo. Precisely,
regulatory B lymphocytes (BREG), which include various
subtypes of IL10-producing cells, have been identified in
the context of autoimmune diseases and exert anti-
inflammatory functions [82, 83]. However, a role for BREG
cells in cancer has not been fully elucidated.
B lymphocytes in general have only recently gained
recognition for representing significant components of tumor
immunity [84]. B cell involvement in solid tumor develop-
ment was initially described in syngeneic allograft murine
tumor models in combination with genetic or antibody-
mediated B cell depletion. In these studies, B cell-deficient
mice (μMT) exhibited resistance to several types of synge-
neic tumors, including EL4 thymoma, MC38 colon carcino-
ma, and B16 and D5 melanoma [85, 86], whereas partial B
cell depletion resulted in significantly reduced tumor burden
in a transplantable model of colorectal cancer [87]. A tumor-
promoting role for B cells in solid tumor development was
also revealed in transgenic mice expressing tumor necrosis
factor (TNF)-receptor-associated factor 3 (TRAF3) in lym-
phocytes [88]. TRAF3
+ lymphocytes induce humoral im-
mune responses leading to chronic inflammation and a
significantly elevated incidence of squamous cell carcinomas
[88]. These experimental findings indicate that, in the absence
of an initiating oncogenic event, B lymphocyte-mediated
chronic inflammation is sufficient to foster solid tumor
formation. In contrast, an opposite and anti-tumor immune
surveillance role for B lymphocytes has also been demon-
strated in a syngeneic melanoma model where deletion of
mature B cells by anti-CD20 IgG significantly enhanced
tumor growth and metastasis [80], suggesting that the role of
B lymphocytes in tumor progression, like CD4
+ Tl y m p h o -
cytes, may be context dependent and driven by individual B
lymphocyte subtype specificity.
Mechanistically, B cells and humoral immunity can act to
modulate solid tumor development by regulation of diverse
effector pathways involving secretion of pro-inflammatory,
as opposed to regulatory, cytokines, e.g., IL10, TGFβ,
inhibition of CTL activity [89], perturbation of TH1/TH2
CD4
+ T cell lineages [90, 91], as well as differential
recruitment and activation of innate immune cells [89, 92].
Recently, using a transgenic mouse model ofinflammation-
associated carcinogenesis, i.e., K14-HPV16 mice [93], we
revealed a novel pathway by which B lymphocytes enhance
squamous carcinogenesis and demonstrated the significance
of the B cell/immunoglobulin/FcγR signaling axis. We found
that B cells and humoral immunity fostered cancer develop-
ment by activating Fcγ receptors on resident and recruited
myeloid cells [74]. Stromal accumulation of autoantibodies in
premalignant skin, through their interaction with activating
FcγRs, regulated recruitment, composition, and bioeffector
functions of leukocytes, in particular subsets of tumor-
promoting polarized myeloid cells in neoplastic tissue which
in turn enhanced neoplastic progression and subsequent
carcinoma development [74]. A similar pro-tumor role for B
cells was recently reported by Ammirante and colleagues
who found that B cells are critical for growth of castration-
resistant prostate cancer metastasis, not through production of
immunoglobulins or regulation of FcγR signaling but instead
by delivery of lymphotoxin that in turn activates IKK-α and
STAT3 in prostate cancer cells and subsequently stimulates
metastasis by an NF-κB-independent, cell-autonomous mech-
anism [94]. These findings together with other experimental
studies support a model in which B cells, through various
mechanisms, including humoral immunity, activating FcγRs
and IKK, are required for establishing chronic inflammatory
programs that promote de novo carcinogenesis.
8 Conclusions
While many factors regulate the propensity of immune cells to
promote or repress solid tumor development, polarized adaptive
immune responses by B and T lymphocytes can specifically
regulate multiple pro-tumor properties of myeloid cells that in
turn control many of the “hallmarks” of cancer development
[95, 96]. Thus, recognition of the soluble molecules that
mediate these important paracrine interactions may represent
critical targets to evaluate for anti-cancer therapy. Importantly,
targeting of pro-tumor pathways that neutralize M2-type
macrophage and/or TH2-type CD4
+ T cell responses and
therein foster M1 or TH1-type immunity may enhance
sensitivity to cytotoxic therapies, including chemo- and
radiation therapy, whose durability may be limited by the
longevity of the anti-tumor immune responses that they induce.
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